Entrada Therapeutics (NASDAQ:TRDA - Get Free Report)'s stock had its "sell (d-)" rating reaffirmed by equities research analysts at Weiss Ratings in a report issued on Wednesday,Weiss Ratings reports.
A number of other equities research analysts have also recently commented on TRDA. Zacks Research upgraded Entrada Therapeutics to a "hold" rating in a report on Friday, August 8th. Wall Street Zen cut Entrada Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, August 9th. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $25.67.
Get Our Latest Analysis on TRDA
Entrada Therapeutics Stock Up 5.3%
Shares of Entrada Therapeutics stock traded up $0.31 on Wednesday, hitting $6.16. The company's stock had a trading volume of 155,599 shares, compared to its average volume of 358,351. Entrada Therapeutics has a 52-week low of $4.93 and a 52-week high of $21.79. The firm has a fifty day moving average price of $5.52 and a 200-day moving average price of $7.03. The company has a market capitalization of $234.31 million, a P/E ratio of -3.46 and a beta of -0.11.
Entrada Therapeutics (NASDAQ:TRDA - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The company reported ($1.04) EPS for the quarter, missing the consensus estimate of ($0.86) by ($0.18). Entrada Therapeutics had a negative return on equity of 17.81% and a negative net margin of 92.30%.The business had revenue of $1.98 million during the quarter, compared to analysts' expectations of $8.17 million. As a group, analysts expect that Entrada Therapeutics will post 1.12 earnings per share for the current year.
Institutional Inflows and Outflows
Large investors have recently made changes to their positions in the company. State of Wyoming raised its position in shares of Entrada Therapeutics by 130.9% in the 2nd quarter. State of Wyoming now owns 7,575 shares of the company's stock worth $51,000 after buying an additional 4,295 shares during the period. Occudo Quantitative Strategies LP purchased a new position in shares of Entrada Therapeutics in the 2nd quarter worth $68,000. IHT Wealth Management LLC purchased a new position in shares of Entrada Therapeutics in the 2nd quarter worth $72,000. Trexquant Investment LP purchased a new position in shares of Entrada Therapeutics in the 1st quarter worth $101,000. Finally, AlphaQuest LLC raised its position in shares of Entrada Therapeutics by 188.2% in the 1st quarter. AlphaQuest LLC now owns 11,662 shares of the company's stock worth $105,000 after buying an additional 7,616 shares during the period. 86.39% of the stock is owned by hedge funds and other institutional investors.
About Entrada Therapeutics
(
Get Free Report)
Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Entrada Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Entrada Therapeutics wasn't on the list.
While Entrada Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
We are about to experience the greatest A.I. boom in stock market history...
Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.
That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.
- The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
- The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
- Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.
Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.
And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...
Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
